UroGen Pharma Ltd. (URGN) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

17/25

Growth 5 Margin 3 Expansion 3 Platform 3 Financial 3

latest quarter score

Earnings Reports

17
UroGen Pharma (URGN) Q2 2026: Zesturi Drives 73% Sequential Launch Growth, Unlocking Community Practice Penetration
August 05, 2026
16
Urogen Pharma (URGN) Q1 2026: Zesturi Prescriber Base Grows 151%, Validating Community Penetration Strategy
May 06, 2026
11
UroGen Pharma (URGN) Q4 2025: Zesturi Launch Drives 21% Revenue Growth, Community Uptake Accelerates
March 02, 2026
13
UroGen Pharma (URGN) Q3 2025: Zesturi Prescriber Base Hits 54 as J-Code Bottleneck Delays Full Uptake
November 06, 2025
14
UroGen Pharma (URGN) Q2 2025: Zysturi Launch Expands Addressable Market to $5B Opportunity
August 07, 2025
8
UroGen Pharma (URGN) Q1 2025: UGN-102 Eyes $5B Market as ODAC Review Nears
July 07, 2025
UroGen Pharma (URGN) Q4 2024: 80.6% Duration of Response Propels UGN-102 Toward Market Launch
March 10, 2025

Browse all companies